Business Context and Reporting Period
Company: NeuroSense Therapeutics Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: March 24, 2026
Context: The filing serves to distribute a press release regarding regulatory and clinical milestones for the company's lead asset, PrimeC. The first six paragraphs of the press release are incorporated by reference into the company's active Registration Statements on Forms S-8 and F-3.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or quantitative financial data.
Material Changes
The filing reports a material update concerning the clinical and regulatory progress of the lead asset, PrimeC. No financial material changes are disclosed in this document.
Guidance, Outlook, and Risks
Management Commentary: The company issued a press release on March 24, 2026, detailing key milestones for PrimeC. Specific details of the outlook or commentary are contained within the attached press release (Exhibit 99.1) and are not summarized in the body of this Form 6-K.
Risks and Contingencies: No specific risks or contingencies are detailed in the text of this filing beyond the standard incorporation of the press release.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 24, 2026) for specific details on the PrimeC regulatory and clinical milestones.
- Verify the incorporation of the press release into the specified Registration Statements (Forms S-8 and F-3).
- Check subsequent filings for any financial updates, as this Form 6-K contains no financial data.